A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 635 participants.

Also called NCT02505334

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 635 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02505334
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02505334. Randomized; no masking; primary purpose treatment. Start 2015-07-21 (actual); primary completion 2017-05-02 (actual). Results posted on 2018-06-25.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02505334
Content hash
37637c186f81565a57ce21cd0b5cdca4a47675d20b5ace23c773d8353838e466